← XTL BIOPHARMACEUTICALS LTD

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue — — — — — — — $41k $451k —
Revenue From Interest — — — — — — — $41k $34k —
Cost of Goods and Services Sold — — — — — — — $31k $338k —
Gross Profit (derived) — — — — — — — $10k $3k —
Research and development $443k $43k $38k $35k $38k $30k $30k $31k $98k —
Operating expenses:
Additional Financial Items
General and administrative $1.3m $1.2m $755k $807k $910k $1.0m $850k $734k $1.6m —
Applicable Tax Rate $0 $0 $0 $0 $0 — — — — —
Average Effective Tax Rate — — — — — — $0 — — —
Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss $3k $9k — — — — — — — —
Finance Income $23k $802k $3.8m $98k $183k $1.5m $1.1m $41k $1.1m —
Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill ($848k) — — — — — — — — —
Profit Loss Attributable To Noncontrolling Interests ($2.5m) ($781k) $3.0m ($1.3m) ($782k) $435k ($1.3m) ($1.8m) ($1.0m) ($7.0m)
Profit Loss Before Tax — — — — — — — ($1.8m) ($1.2m) —
Profit Loss From Operating Activities ($2.6m) ($1.2m) ($793k) ($842k) ($948k) ($1.0m) ($880k) ($765k) ($2.2m) ($1.7m)
Operating loss ($2.6m) ($1.2m) ($793k) ($842k) ($948k) ($1.0m) ($880k) ($765k) ($2.2m) ($1.7m)
Change in fair value of financial instruments — — — — — — $1.1m — $926k $1.1m
Change in fair value of marketable securities — — — — — — ($1.5m) ($1.0m) $167k $5k
Other finance income — $37k $87k $98k $45k — $36k $41k $34k $60k
Loss before income taxes — — — — — — ($1.3m) ($1.8m) ($1.2m) ($759k)
Profit (loss) from continuing operations — — — — — — — ($1.8m) $240k ($759k)
Loss from discontinued operations, net of tax — — — — — — — — ($1.3m) ($6.2m)
Net loss for the year ($2.5m) ($781k) $3.0m ($1.3m) ($782k) $435k ($1.3m) ($1.8m) ($1.0m) ($7.0m)
Basic Earnings (Loss) Per Share — — — — — $0.00 ($0.00) ($0.00) ($0.00) —
Diluted Earnings (Loss) Per Share — ($0.00) $0.01 ($0.00) ($0.00) $0.00 ($0.00) ($0.00) ($0.00) ($0.01)
Profit (loss) from continuing operations (in Dollars per share) — — — — — — — ($0.00) $0.00 ($0.00)
Diluted profit (loss) from continuing operations (in Dollars per share) — — — — — — — ($0.00) $0.00 ($0.00)
Loss from discontinued operations (in Dollars per share) — — — — — — — — ($0.00) ($0.01)
Diluted loss from discontinued operations (in Dollars per share) — — — — — — — — ($0.00) ($0.01)
Weighted average number of issued ordinary shares (in Shares) — $470.2m $514.2m $514.2m $514.2m — $544.9m $544.9m $673.0m $896.2m
Diluted weighted average number of ordinary shares (in Shares) — — — — — — $544.9m $544.9m $704.2m $896.2m
Research and development expenses — ($43k) ($38k) ($35k) ($38k) — ($30k) ($31k) ($98k) ($28k)
General and administrative expenses — ($1.2m) ($755k) ($807k) ($910k) — ($850k) ($734k) ($1.6m) ($1.4m)
Deferred Tax Expense (Income) — — — — — — — — ($130k) —
Deferred Tax Expense (Income) Recognised In Profit Or Loss — — — — — — — — $130k —
Depreciation And Amortisation Expense $3k $1k — — — — — — — —
Employee Benefits Expense $551k $424k $312k $302k $329k $276k $276k $243k $605k —
Expense From Share-Based Payment Transactions With Employees $175k $37k $22k $5k $51k $37k $14k — — —
Finance Costs $7k $337k $35k $603k $17k $21k $1.6m — — —
Other Finance Cost $7k $8k $35k $29k $17k $21k $27k $36k $112k —
Postemployment Benefit Expense Defined Contribution Plans $17k $11k $6k $6k $2k $0 — — — —
Professional Fees Expense $213k $440k $255k $262k $266k $381k $291k — — —
Other finance expenses — ($8k) ($35k) ($29k) ($17k) — ($27k) ($36k) ($112k) ($177k)
Finance income (expenses), net — $465k $3.8m ($505k) $166k — ($468k) ($1.0m) $1.0m $929k
Interest Expense — — — — — — — — $28k —
Income Tax Expense Continuing Operations — — — — — — — — ($130k) —

Data sourced from SEC EDGAR 10-K filings via EdgarTools. Amounts are shown in USD as reported in each fiscal year filing.